OptimizeRx Corp. (OPRX)
Valuation Overview•Is OptimizeRx Corp. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Moderate quality score of 71/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
OPRX demonstrates adequate business quality with stable profitability. This is paired with a moderately leveraged but stable balance sheet.
The company is driving exceptional top-line expansion (20.6% 3Y CAGR) paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 11.4%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $20.5M | +18.8% | +20.6% | +20.4% | +31.2% | |
| EBITDA | $976K | — | — | — | — | |
| Net Income | -$703K | +125.5% | — | — | — | |
| EPS (Diluted) | $-0.04 | +124.5% | — | — | — | |
| Free Cash Flow | $8.6M | +290.6% | +21.5% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 72.1% | 62.6% | 61.7% | 58.9% |
| Operating Margin | 11.4% | -13.6% | -12.0% | -11.7% |
| Net Margin | 4.7% | -13.9% | -11.9% | -11.3% |
| FCF Margin | 18.6% | 3.6% | 5.6% | -2.0% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q3'26Latest | $0.11 | $0.16 | +44.0% | ||
| Q2'26 | $0.01 | $0.14 | +1300.0% | ||
| Q1'26 | $0.23 | $0.51 | +121.7% | ||
| Q4'25 | $0.03 | $0.20 | +566.7% | ||
| Q3'25 | $0.03 | $0.24 | +700.0% | ||
| Q2'25 | $-0.11 | $0.08 | +172.7% | ||
| Q1'25 | $0.25 | $0.30 | +20.0% | ||
| Q4'24 | $0.06 | $0.12 | +100.0% |
Total return is -60.1% (1Y), lagging the benchmark by -75.9%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -38.8% | -51.2% | — |
| 1Y | -60.1% | -75.9% | — |
| 3YCAGR | +0.8% | -20.7% | — |
| 5YCAGR | -37.4% | -48.6% | — |
| 10YCAGR | +8.9% | -4.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about OptimizeRx Corp. (OPRX) valuation, health, and returns.
Based on peer relative multiples, OptimizeRx Corp. appears Cheap versus peers compared to industry peers.
OptimizeRx Corp. has multiple valuation anchors: Peer Relative Fair Value: $13.97 | Wall Street Analyst Target: $10.25 (implying +34.9% upside). A convergence of these signals offers higher conviction.
OptimizeRx Corp. displays good financial health with a composite quality score of 71/100, supported by a Altman Z-Score of 2.0 (grey zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 6.8%.
OptimizeRx Corp. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
OptimizeRx Corp.'s current growth trajectory is Stable. The company achieved +18.8% 1Y revenue growth and +124.5% 1Y EPS growth, compared to its 3Y revenue CAGR of +20.6%.
Wall Street consensus is Buy based on 15 analysts, beating EPS expectations in 83% of recent quarters with a 9-quarter streak. The consensus price target represents a +34.9% change from current levels.
Investment risks for OptimizeRx Corp. include: -79.1% 1-year max drawdown, high beta (1.93x market volatility). Volatility risk is characterized by a beta of 1.93x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.